Merit Medical Hypotube Manufacturing Business Is Acquired by Freudenberg Medical

September 8, 2020

Freudenberg Medical, a global developer and manufacturer of specialty components and finished products for the medical device industry, has acquired the dedicated manufacturing equipment and associated assets utilized by Merit Medical Systems, Inc. in its hypotube manufacturing business.

Freudenberg Medical notes the acquired assets will be absorbed by Cambus Medical located in Galway, Ireland. Cambus Medical, a Freudenberg Medical company, is a market-leading hypotube manufacturer in the minimally invasive industry. Established in 2006, Cambus Medical develops and manufactures hypotubes, specialty needles, and metal micro-components for catheters and minimally invasive devices used in diagnostic and therapeutic interventions.

The acquisition includes manufacturing equipment for laser-cut hypotubes and access to additional technology. Merit Medical will supply Cambus Medical with PTFE coated tubing and wire to ensure uninterrupted product supply for all existing customers.

“This transaction is a key step in expanding our leading position in the hypotube market for catheters and other minimally invasive devices,” said Dr. Max Kley, CEO of Freudenberg Medical. “Freudenberg Medical covers the full value chain from supplying mission-critical components like hypotubes to full device manufacturing. This level of vertical integration puts us into a unique position to offer the most advanced technical solutions to our minimally invasive device customers.”

Barry Comerford, CEO of Cambus Medical states, “this strategic acquisition will give Cambus Medical key equipment to increase production capacity, deepen our technology base to achieve unrivaled laser processing and coating capabilities, and expand our customer base.”

Freudenberg Medical’s comprehensive catheter development capabilities include advanced extrusion, handle and shaft development, balloon development and manufacturing, hypotubes and metal micro-components, assembly, and coatings.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”